aTyr Pharma (ATYR) Competitors $0.89 -0.06 (-6.07%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$0.89 0.00 (-0.26%) As of 09/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. OCUL, BLTE, IDYA, AGIO, ANIP, RXRX, TVTX, BEAM, TARS, and IRONShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), Recursion Pharmaceuticals (RXRX), Travere Therapeutics (TVTX), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals ANI Pharmaceuticals Recursion Pharmaceuticals Travere Therapeutics Beam Therapeutics Tarsus Pharmaceuticals Disc Medicine Ocular Therapeutix (NASDAQ:OCUL) and aTyr Pharma (NASDAQ:ATYR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Which has higher valuation and earnings, OCUL or ATYR? aTyr Pharma has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M33.42-$193.51M-$1.28-9.56aTyr Pharma$230K380.58-$64.02M-$0.80-1.12 Is OCUL or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Ocular Therapeutix's return on equity of -71.92% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% aTyr Pharma N/A -93.69%-68.83% Does the media prefer OCUL or ATYR? In the previous week, aTyr Pharma had 7 more articles in the media than Ocular Therapeutix. MarketBeat recorded 11 mentions for aTyr Pharma and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.12 beat aTyr Pharma's score of 0.45 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer OCUL or ATYR? Ocular Therapeutix presently has a consensus price target of $17.83, suggesting a potential upside of 45.70%. aTyr Pharma has a consensus price target of $23.25, suggesting a potential upside of 2,502.71%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Do institutionals & insiders have more ownership in OCUL or ATYR? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, OCUL or ATYR? Ocular Therapeutix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. SummaryaTyr Pharma beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.18M$3.13B$5.74B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-1.1220.6375.7726.11Price / Sales380.58442.69544.60124.93Price / CashN/A44.6737.5461.24Price / Book1.089.6212.876.30Net Income-$64.02M-$52.73M$3.29B$271.03M7 Day Performance-9.96%1.81%0.26%-0.14%1 Month Performance-82.62%5.50%2.85%5.82%1 Year Performance-48.66%18.12%65.65%27.63% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma2.4898 of 5 stars$0.89-6.1%$23.25+2,502.7%-48.1%$93.18M$230K-1.1253OCULOcular Therapeutix3.78 of 5 stars$12.54-2.1%$17.83+42.2%+38.5%$2.23B$63.72M-9.80230Positive NewsBLTEBelite Bio2.82 of 5 stars$66.80-3.9%$96.00+43.7%+50.7%$2.21BN/A-43.1010High Trading VolumeIDYAIDEAYA Biosciences3.9832 of 5 stars$24.53-0.3%$42.85+74.7%-15.4%$2.16B$7M-6.4780AGIOAgios Pharmaceuticals4.2553 of 5 stars$36.30-1.3%$56.00+54.3%-25.3%$2.14B$36.50M3.30390ANIPANI Pharmaceuticals4.0419 of 5 stars$98.81+1.1%$88.25-10.7%+63.0%$2.12B$614.38M-128.32600Analyst ForecastRXRXRecursion Pharmaceuticals2.2385 of 5 stars$4.77-1.2%$7.25+52.0%-32.8%$2.10B$58.84M-2.68400Positive NewsGap DownTVTXTravere Therapeutics2.8865 of 5 stars$23.01-2.0%$34.20+48.6%+69.2%$2.09B$233.18M-11.28460Insider TradeBEAMBeam Therapeutics3.0007 of 5 stars$21.28+3.3%$46.40+118.0%-5.8%$2.08B$63.52M-4.73510Gap DownTARSTarsus Pharmaceuticals2.041 of 5 stars$49.59+0.5%$66.67+34.4%+71.1%$2.08B$182.95M-21.2850Positive NewsIRONDisc Medicine3.2006 of 5 stars$59.90+0.1%$98.30+64.1%+30.6%$2.08BN/A-13.4030Positive News Related Companies and Tools Related Companies Ocular Therapeutix Alternatives Belite Bio Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives Travere Therapeutics Alternatives Beam Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATYR Stock Alerts